Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cobra Biologics and Recopharma Enter Agreement

Published: Wednesday, May 29, 2013
Last Updated: Tuesday, May 28, 2013
Bookmark and Share
Agreement to utilize Cobra’s cell line development service- MaxXpress.

Cobra Biologics Ltd and Recopharma have announced an agreement to supply a human Fc fusion protein using Cobra’s maxXpress service.

Cobra Biologics will apply its cost-effective maxXpress platform service to deliver a programme of vector construction using the UCOE technology, transfectant pool generation, and supply, purification and protein characterization.

The service allows Recopharma to form a quick and reliable assessment on the specific expertise of Cobra’s cell line development and analytical scientist teams.

Recopharma has developed a unique technology that uses mucins, naturally occurring proteins produced by epithelial tissues with many potential applications.

The FC fused mucins will provide a natural alternative to ocular lubricants and tear substitutes that are at present available and set to be used as a treatment and prophylactic that tackles viral conjunctivitis.

Peter Coleman CEO of Cobra Biologics commented: “I am very pleased that Recopharma has chosen Cobra to supply pre-clinical material. Cobra’s maxXpress service has proven very popular with customers. Indeed, the service allows customers to make a fast assessment as to whether the UCOE technology and cell development team are the best combination to take their protein forward to clinical trials”.

Jan Holgersson, CEO/ CSO of Recopharma said “We are very excited about working with Cobra Biologics, and to apply their cell line development expertise on our mucin-type fusion proteins. A cell pool providing good yields will be an important commercial milestone on our path towards clinical studies with our dry eye disease lead compound.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cobra Biologics, Alligator Bioscience Announce Partnership
Partnership aims to develop second cell line for manufacture of immuno-oncology antibody ADC-1015 following ADC-1013 success.
Friday, June 24, 2016
Cobra Biologics, CPI Announce Collaboration
Cobra Biologics and the Centre for Process Innovation are collaborating on a project which will focus on the development of an Industrial Manufacturing Platform for Adeno-Associated Virus (AAV) production to support gene therapy and regenerative medicine.
Thursday, February 25, 2016
Cobra Biologics Appointed by University of Sheffield
Manufacturing service will scale production of growth hormone developed using ‘ProFuse’ Technology.
Tuesday, November 24, 2015
Cobra Biologics, The University of Manchester Announce Collaboration
Agreement brings together academic and industrial expertise for the scaled manufacture of therapeutic proteins.
Friday, September 25, 2015
Cobra Biologics and The University of Manchester Announce Collaboration
Agreement brings together academic and industrial expertise for the scaled manufacture of therapeutic proteins.
Friday, September 25, 2015
Cobra Biologics and Tecrea Awarded £112K Innovate UK Grant to Develop AAV Scalable Production Bioprocess
‘Technology Inspired Innovation’ award to evaluate robust, large scale viral vector production.
Thursday, April 02, 2015
Cobra Biologics & The University of Manchester Receive £217K Innovate UK/BBSRC Funding
Awarded as part of £20M competition bringing innovative biotechnology projects to market.
Monday, February 23, 2015
Cobra Biologics Appoints CSO
Company announces the appointment of Dr Daniel C. Smith as its Chief Scientific Officer.
Wednesday, May 07, 2014
Cobra Biologics, BioCancell Agreement for Promising Cancer Therapy Drug
The Companies have announced the agreement to manufacture BioCancell’s BC-821 cancer drug for clinical trials.
Monday, March 03, 2014
GMP Certification Boost for Cobra Biologics
Extended certification to include QC testing of registered products.
Wednesday, February 12, 2014
Cobra Biologics and Novolytics Develop Bacteriophages Against Infection
Companies have achieved a breakthrough in the development of two Staphylococcus aureus-based phage products for Phase I clinical trials.
Wednesday, June 12, 2013
Cobra Biologics and Vaccibody Sign Agreement to Manufacture DNA Vaccine
Companies announce agreement to manufacture Vaccibody’s lead DNA vaccine candidate against HPV-induced malignancies.
Tuesday, May 14, 2013
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors
Programmable T cells shown to be versatile, precise, and powerful in lab studies.
Monkeys Protected by Zika DNA Vaccine
Experimental Zika virus DNA vaccines successfully protected monkeys against Zika infection.
New Weapon Against Hard-to-Treat Bacterial Infections
Using peptides, researchers have been able to prevent drug-resistance bacteria from forming abscesses.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Vaccine Against Common Cold Achievable
Researchers suggest that a vaccine against rhinoviruses is possible using variant virus vaccines.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!